Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 21, 2014; 20(23): 7079-7088
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7079
Table 1 Protease inhibitors currently under development
First generation (wave 2)
Simeprevir
Faldaprevir
Danoprevir
Vaniprevir
ABT-450/ABT-450r
Asunaprevir
Second generation
MK-5172
ACH-2684
Table 2 Additional drugs in development for hepatitis C
NS5A hepatitis C virus replication inhibitors
Daclatasvir
Ledipasvir
ACH-3102
ABT-267
NS5B RNA dependent RNA polymerase inhibitors
Sofosbuvir
Mericitabine
ABT-333
Host targeted agents
Alisporivir
Miravirsen
Interferon-λ